桑多斯的Enzeevu,一种可互换的nAMD生物类似药,获得美国FDA的批准. Sandoz's Enzeevu, an interchangeable biosimilar for nAMD, receives US FDA approval.

桑多斯公司的Enzeevu,一种用于治疗新血管与年龄相关的黄斑退化 (nAMD) 的生物类似药物,获得美国FDA的批准,加强了美国眼科产品组合. Sandoz's Enzeevu, a biosimilar treatment for neovascular age-related macular degeneration (nAMD), receives US FDA approval, strengthening its US ophthalmology portfolio. NAMD的Nzeevu是美国第一个可互换的生物型样,目的是改善和保持受影响病人的视觉敏锐性。 Enzeevu is the first interchangeable biosimilar in the US for nAMD and aims to improve and maintain visual acuity in affected patients. 该批准推进了山德士的增长战略，并增强了在美国生物仿制药的地位，增加了受这一主要原因影响的50岁以上患者视力障碍患者的治疗机会。 The approval advances Sandoz's growth strategy and enhances the US biosimilar position, increasing treatment access for patients affected by this leading cause of vision impairment in patients over 50 years.